Paper33740902
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
Kudrow D and 6 others. BMC Neurol, 2021. Cited by 69 papers, by iCite.
Cite this record
ConductScience Library. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. Papers, record 33740902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33740902
- Disease
- migraine disorder166 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Calcitonin Gene-Related Peptide | Major topic |
| Migraine Disorders | Major topic |
| Administration, Intravenous | |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Nasopharyngitis | |
| Patient Reported Outcome Measures | |
| Quality of Life | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02985398 | An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine | Derived from the trial | Yes |
Source ClinicalTrials.gov
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29368949 | Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. | Cephalalgia | 2018 | https://conductscience.org/library/papers/29368949 | PubMed |
| 2 | 30661365 | CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. | Cephalalgia | 2019 | https://conductscience.org/library/papers/30661365 | PubMed |
| 3 | 28984356 | A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns. | Headache | 2017 | https://conductscience.org/library/papers/28984356 | PubMed |
| 4 | 25304766 | The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. | Cephalalgia | 2015 | https://conductscience.org/library/papers/25304766 | PubMed |
| 5 | 30446596 | Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. | Neurology | 2018 | https://conductscience.org/library/papers/30446596 | PubMed |
| 6 | 14651415 | A six-item short-form survey for measuring headache impact: the HIT-6. | Qual Life Res | 2003 | https://conductscience.org/library/papers/14651415 | PubMed |
| 7 | 28409893 | Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. | Clin Pharmacol Drug Dev | 2017 | https://conductscience.org/library/papers/28409893 | PubMed |
| 8 | 23458496 | Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). | Headache | 2013 | https://conductscience.org/library/papers/23458496 | PubMed |
| 9 | 32366601 | Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide. | J Pharmacol Exp Ther | 2020 | https://conductscience.org/library/papers/32366601 | PubMed |
| 10 | 29697154 | A Phase-by-Phase Review of Migraine Pathophysiology. | Headache | 2018 | https://conductscience.org/library/papers/29697154 | PubMed |
| 11 | 20819842 | Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. | Cephalalgia | 2011 | https://conductscience.org/library/papers/20819842 | PubMed |
| 12 | 21762134 | Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). | Headache | 2011 | https://conductscience.org/library/papers/21762134 | PubMed |
| 13 | 29691490 | CGRP as the target of new migraine therapies - successful translation from bench to clinic. | Nat Rev Neurol | 2018 | https://conductscience.org/library/papers/29691490 | PubMed |
| 14 | 28919117 | Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. | Lancet | 2017 | https://conductscience.org/library/papers/28919117 | PubMed |
| 15 | 32075406 | Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). | Cephalalgia | 2020 | https://conductscience.org/library/papers/32075406 | PubMed |
| 16 | 25297013 | Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. | Lancet Neurol | 2014 | https://conductscience.org/library/papers/25297013 | PubMed |
| 17 | 30536394 | The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. | Headache | 2019 | https://conductscience.org/library/papers/30536394 | PubMed |
| 18 | 29171818 | Fremanezumab for the Preventive Treatment of Chronic Migraine. | N Engl J Med | 2017 | https://conductscience.org/library/papers/29171818 | PubMed |
| 19 | 32209650 | Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. | Neurology | 2020 | https://conductscience.org/library/papers/32209650 | PubMed |
| 20 | 29504482 | Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. | Cephalalgia | 2018 | https://conductscience.org/library/papers/29504482 | PubMed |
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42348309 | ESTELA-Study: Long-Term Effectiveness and Safety of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Real-World Clinical Practice. | Brain Behav | 2026 | https://conductscience.org/library/papers/42348309 | PubMed |
| 42201619 | CGRP-targeted therapies for migraine and the risk of infection. | Intern Emerg Med | 2026 | https://conductscience.org/library/papers/42201619 | PubMed |
| 41996064 | Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial. | Pain Ther | 2026 | https://conductscience.org/library/papers/41996064 | PubMed |
| 41484941 | Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review. | J Headache Pain | 2026 | https://conductscience.org/library/papers/41484941 | PubMed |
| 41383230 | SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway-targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials. | Front Neurol | 2025 | https://conductscience.org/library/papers/41383230 | PubMed |
| 41275111 | Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial. | J Headache Pain | 2025 | https://conductscience.org/library/papers/41275111 | PubMed |
| 40838472 | Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study. | Eur J Neurol | 2025 | https://conductscience.org/library/papers/40838472 | PubMed |
| 40628864 | Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment. | Sci Rep | 2025 | https://conductscience.org/library/papers/40628864 | PubMed |
| 40444655 | Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine. | Headache | 2025 | https://conductscience.org/library/papers/40444655 | PubMed |
| 40329208 | Unmasking the relationship between CGRP and glutamate: from peripheral excitation to central sensitization in migraine. | J Headache Pain | 2025 | https://conductscience.org/library/papers/40329208 | PubMed |
| 40033803 | Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort study. | Headache | 2025 | https://conductscience.org/library/papers/40033803 | PubMed |
| 39501727 | Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial. | Headache | 2025 | https://conductscience.org/library/papers/39501727 | PubMed |
| 38938785 | Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications. | Front Neurol | 2024 | https://conductscience.org/library/papers/38938785 | PubMed |
| 38664605 | Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study. | J Headache Pain | 2024 | https://conductscience.org/library/papers/38664605 | PubMed |
| 38637754 | An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity. | J Headache Pain | 2024 | https://conductscience.org/library/papers/38637754 | PubMed |
| 38549121 | Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab. | J Headache Pain | 2024 | https://conductscience.org/library/papers/38549121 | PubMed |
| 38523607 | Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. | Front Neurol | 2024 | https://conductscience.org/library/papers/38523607 | PubMed |
| 38405041 | Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence. | Saudi Pharm J | 2024 | https://conductscience.org/library/papers/38405041 | PubMed |
| 38308209 | Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. | J Headache Pain | 2024 | https://conductscience.org/library/papers/38308209 | PubMed |
| 38236314 | Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study. | Neurol Ther | 2024 | https://conductscience.org/library/papers/38236314 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CALCA | 796 | PubTator's text mining | https://conductscience.org/library/genes/796 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| EPTINEZUMAB | CHEMBL3833320 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3833320 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33740902
GET https://conductscience.org/api/papers/v1/33740902/references?page=2